Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

Bullboard (TSX:TH)

View:
Prev ... 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 ... Next
Post by Mannequinon May 27, 2024 8:09am

AI Conclusion of Abstract

### Interpretation and Considerations   1. **Efficacy:**    - The stabilization of disease in a heavily pretreated population, along with a partial response and complete response ...more  
192
Post by Mannequinon May 27, 2024 8:04am

ASCO Info

I let the most advanced AI that I have access to review several ASCO abstracts from other companies. It concluded that these other companies were not really getting the results necessary in the ...more  
209
Discussion
Comment by Mannequinon May 26, 2024 2:26pm

RE:RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

It is sad it potentially could have helped, and I wonder if anyone else in her situation has been put through the program with ovarian cancer and seen any benefit. There is not much explained thus far ...more  
139
Discussion
Comment by juniper88on May 26, 2024 11:45am

RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

The biomarker for ovarian cancer is CA-125. With my wife after 1 infusion of TH1902 it dropped by over 40%.  I remember Dr. Winers assistant coming back to us with a smile.  We were very ...more  
156
Discussion
Comment by SPCEO1on May 25, 2024 6:59pm

RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

I don't know if I really feel like I recovered asI felt fine before getting my stents, the procedure placing the stents was a breeze and I have felt fine ever since. The only improvement I have ...more  
141
Discussion
Comment by SPCEO1on May 25, 2024 12:53pm

RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

I am glad there are other treatment options for you but sad to hear of your declining quality of life. You have battled this beast for a very long time and I am sure it takes an emotional as well as ...more  
96
Discussion
Comment by jfm1330on May 25, 2024 12:20pm

RE:RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

I don't know if they can attract a partner. That being said, a big pharma like Bristol Myers Squibb now has this expertise. They bought RayzeBio for 4.1 B$ and their main drug candidate is 225 Ac ...more  
114
Discussion
Comment by Mannequinon May 25, 2024 10:48am

RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

As they have FDA Fast Track, do you think there is any leniency at the FDA for amending the trial (with a partner who has experience) to add Ga68 without having to start the trial from scratch?   ...more  
99
Discussion
Comment by jfm1330on May 25, 2024 9:08am

RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

The strong scientific rationale was there from the beginning. A company with real financial means and stong scientific people would have integrated it in their clinical protocol from the beginning. I ...more  
95
Discussion
Comment by Mannequinon May 25, 2024 3:56am

RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

The cannot start a Ga68 trial without evidence. Coupling a clinical trial with Ga-68 (Gallium-68) involves using this radioisotope in conjunction with a PET scan to enhance the imaging and diagnostic ...more  
99
Discussion
Comment by jfm1330on May 24, 2024 7:49pm

RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

If all they have on humans is stable disease, even on half of the patients, it will be hard to attract a partner, again, because it means the long and costly road to approval and they have nothing ...more  
132
Discussion
Prev ... 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities